Forge Bio’s Combo Model for Gene Therapies Attracts $40M in Funding

▤ Summary

Now it has $40 million to expand its model, which places contract manufacturing alongside the development of its own gene therapies, the most advanced of which is being readied for tests in humans. The explosion of gene therapy research is leading to growing demand for manufacturing capabilities—much more than the industry is forecast to supply in coming years. The most advanced Forge program is a gene therapy for Krabbe disease, an inherited neurological disorder caused by a loss of myelin, a protective covering of the nerve cells. The most common form of Krabbe affects infants and leads to problems such as muscle weakness, difficulty eating, and delayed physical and mental development. According to preclinical research published in 2011 in The Journal of Neuroscience, the combination of a bone marrow transplant and gene therapy helped on several measures, including … Next Page »

▦ Linked Companies

Shareaholic

$1M to $5M